HBP.F · Helix BioPharma Corp

-

Please sign in to comment on HBP.F

1 Comment

Admin

4 years ago

Helix BioPharma Corp is currently in a long term uptrend where the price is trading 36.6% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Helix BioPharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 11.7% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 37.4% to $-3M since the same quarter in the previous year.

Based on the above factors, Helix BioPharma Corp gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	None
Sector
Industry

Market Cap	78M
PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Beta	-0.67

ABOUT

Helix BioPharma Corp

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.

HBP.F · Helix BioPharma Corp

-

Helix BioPharma Corp

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Helix BioPharma Corp using a moving average strategy